In one case report, a patient demonstrated a radiographic complete response to this olaparib/pembrolizumab combination in the maintenance setting, albeit in the atypical context of harboring both a germline BRCA1 mutation and an extremely high tumor mutational burden [51]. Here, BRCA1 is linked to neoplasm.